Caricamento...

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common adult leukemia, with an overall poor prognosis. New agents targeting various receptors may improve treatment outcomes and overall survival. FMS-like tyrosine kinase 3 (FLT3) is a targetable mutation occurring in one third of AML patients. It contribute...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Adv Pract Oncol
Autori principali: Marjoncu, Dennis, Andrick, Benjamin
Natura: Artigo
Lingua:Inglês
Pubblicazione: Harborside Press LLC 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7517771/
https://ncbi.nlm.nih.gov/pubmed/33542854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.1.7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !